| Name | Title | Contact Details |
|---|
American Nuclear Insurers (ANI) is a joint underwriting association created by some of the largest insurance companies in the United States. Our purpose is to pool the financial assets pledged by our member companies to provide the significant amount of property and liability insurance required for nuclear power plants and related facilities throughout the world.
Syensqo is a leading science company whose ground-breaking technologies revolutionize the way we live. Our purpose is to advance human progress while cultivating a future for our planet that is not only safer and cleaner, but also inherently more sustainable, driven by the principles of circular economy. Our disruptive, market-leading solutions address fundamental megatrends. We play a key role in the future of clean mobility and bring about breakthroughs in biotechnology, natural ingredients, and circular solutions, contributing to sustainable, high-performance products for homes, food and consumer goods, planes, cars, smart devices, and healthcare applications. Inspired by the scientific councils, which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.
Excellus BlueCross BlueShield, a nonprofit independent licensee of the BlueCross BlueShield Association, is part of a family of companies that finances and delivers vital health care services to about 1.5 million people across upstate New York. Excellus BlueCross BlueShield provides access to high-quality, affordable health coverage, including valuable health-related resources that our members use every day, such as cost-saving prescription drug discounts and wellness tracking tools. To learn more, visit excellusbcbs.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.